EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Evaluation of Molecular Residual Disease by a Fixed Panel in Resectable Colorectal Cancer

Jian Yang, Chengqing Yu, Haoran Li, Di Peng, Qiaoxia Zhou, Jun Yao, Juan Lv, Shuai Fang, Jiaochun Shi, Yijun Wei, Guoqiang Wang, Shangli Cai und 3 weitere

Cancer Research and Treatment · 2024

DOI: 10.4143/crt.2023.1371 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, 2024. Verfasst von Jian Yang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The First Affiliated Hospital of Soochow University, Jiangsu, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Neoplasm, Residual, Circulating Tumor DNA, Biomarkers, Tumor. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Suzhou Science and Technology Bureau medical health technology innovation project, Soochow University, Project of Medical Applied and Basic Research Foundation of Suzhou Science & Technology Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Molecular residual disease (MRD) is a promising biomarker in colorectal cancer (CRC) for prognosis and guiding treatment, while the whole-exome sequencing (WES) based tumor-informed assay is standard for evaluating MRD based on circulating tumor DNA (ctDNA). In this study, we assessed the feasibility of a fixed-panel for evaluating MRD in CRC.Materials and Methods Seventy-five patients with resectable stage I-III CRC were enrolled. Tumor tissues obtained by surgery, and preoperative and postoperative day 7 blood samples were collected. The ctDNA was evaluated using the tumor-agnostic and tumor-informed fixed assays, as well as the WES-based and panel-based personalized assays in randomly selected patients.

Results

The tumor-informed fixed assay had a higher preoperative positive rate than the tumor-agnostic assay (73.3% vs. 57.3%). The preoperative ctDNA status failed to predict disease-free survival (DFS) in either of the fixed assays, while the tumor-informed fixed assay-determined postoperative ctDNA positivity was significantly associated with worse DFS (hazard ratio [HR], 20.74; 95% confidence interval [CI], 7.19 to 59.83; p < 0.001), which was an independent predictor by multivariable analysis (HR, 28.57; 95% CI, 7.10 to 114.9; p < 0.001). Sub-cohort analysis indicated the WES-based personalized assay had the highest preoperative positive rate (95.1%). The two personalized assays and the tumor-informed fixed assay demonstrated same results in postoperative landmark (HR, 26.34; 95% CI, 6.01 to 115.57; p < 0.001), outperforming the tumor-agnostic fixed panel (HR, 3.04; 95% CI, 0.94 to 9.89; p=0.052).

Conclusion

Our study confirmed the prognostic value of the ctDNA positivity at postoperative day 7 by the tumor-informed fixed panel. The tumor-informed fixed panel may be a cost-effective method to evaluate MRD, which warrants further studies in future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsNeoplasm, ResidualCirculating Tumor DNABiomarkers, TumorHumansMaleFemaleAgedMiddle AgedPrognosisExome SequencingAged, 80 and overAdultNeoplasm Staging

Stichwörter der Autor:innen

Circulating tumor DNAFixed panelHigh-throughput nucleotide sequencingMolecular residual diseasePersonalized panelTumor-agnosticTumor-informed

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Department of General Surgery, The First Affiliated Hospital of Soochow University, Jiangsu, China.
  • Burning Rock Biotech, Guangdong, China.
  • Department of General Surgery, The Dushu Lake Hospital Affiliated to Soochow University, Jiangsu, China.

Förderung

  • Suzhou Science and Technology Bureau medical health technology innovation project
  • Soochow University
  • Project of Medical Applied and Basic Research Foundation of Suzhou Science & Technology Bureau
  • Project of the First Hospital of Soochow University Natural Science Foundation Incubation Programme for Doctoral Trainees
  • Project of Extracurricular Academic Research of Soochow University

Zitieren

APA

Yang, J., Yu, C., Li, H., Peng, D., Zhou, Q., Yao, J., Lv, J., Fang, S., Shi, J., Wei, Y., Wang, G., Cai, S., Zhang, Z., Zhang, Z., & Zhou, J. (2024). Evaluation of Molecular Residual Disease by a Fixed Panel in Resectable Colorectal Cancer. Cancer Research and Treatment. https://doi.org/10.4143/crt.2023.1371

Vancouver

Yang J, Yu C, Li H, Peng D, Zhou Q, Yao J, et al. Evaluation of Molecular Residual Disease by a Fixed Panel in Resectable Colorectal Cancer. Cancer Research and Treatment. 2024. doi:10.4143/crt.2023.1371

BibTeX
@article{Yang2024,
  author = {Yang, Jian and Yu, Chengqing and Li, Haoran and Peng, Di and Zhou, Qiaoxia and Yao, Jun and Lv, Juan and Fang, Shuai and Shi, Jiaochun and Wei, Yijun and Wang, Guoqiang and Cai, Shangli and Zhang, Zhihong and Zhang, Zixiang and Zhou, Jian},
  title = {Evaluation of Molecular Residual Disease by a Fixed Panel in Resectable Colorectal Cancer},
  journal = {Cancer Research and Treatment},
  year = {2024},
  doi = {10.4143/crt.2023.1371}
}
Kostenlos starten →